NO20016226D0 - Fremgangsmåte for fremstilling av substituerte formamider - Google Patents

Fremgangsmåte for fremstilling av substituerte formamider

Info

Publication number: NO20016226D0
Authority: NO; Norway
Prior art keywords: preparation; substituted formamides; formamides; substituted; tosylbenzyl
Prior art date: 1995-01-09

Application number

NO20016226A

Other languages

English (en)

Other versions

NO20016226L (no

Inventor

Jerry Leroy Adams

Timothy F Gallagher

Ravi Shanker Garigipati

Jeffrey Charles Boehm

Joseph Sisko

John Cheung-Lun Lee

Original Assignee

Smithkline Beecham Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-01-09

Filing date

2001-12-19

Publication date

2001-12-19

1997-09-08 Publication of NO20016226L publication Critical patent/NO20016226L/no

2001-12-19 Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp

2001-12-19 Publication of NO20016226D0 publication Critical patent/NO20016226D0/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C315/00—Preparation of sulfones; Preparation of sulfoxides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/38—One sulfur atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Physical Education & Sports Medicine (AREA)
Diabetes (AREA)
Virology (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Hematology (AREA)
Pulmonology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Neurosurgery (AREA)
Obesity (AREA)
Cardiology (AREA)
Molecular Biology (AREA)
Heart & Thoracic Surgery (AREA)
Dermatology (AREA)
Immunology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Tropical Medicine & Parasitology (AREA)
Psychiatry (AREA)

NO20016226A 1995-01-09 2001-12-19 Fremgangsmåte for fremstilling av substituerte formamider NO20016226D0 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US36996495A	1995-01-09	1995-01-09
US08/472,366 US5593992A (en)	1993-07-16	1995-06-07	Compounds
PCT/US1996/000546 WO1996021452A1 (en)	1995-01-09	1996-01-11	Certain 1,4,5-tri-substituted imidazole compounds useful as cytokine

Publications (2)

Publication Number	Publication Date
NO20016226L NO20016226L (no)	1997-09-08
NO20016226D0 true NO20016226D0 (no)	2001-12-19

Family

ID=27004764

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
NO973167A NO973167L (no)	1995-01-09	1997-07-08	Bestemte 1,4,5-trisubstituerte imidazol-forbindelser anvendelige som cytokin
NO20016225A NO20016225D0 (no)	1995-01-09	2001-12-19	Fremgangsmåte for fremstilling av 1,4,5-trisubstituerte imidazolforbindelser
NO20016226A NO20016226D0 (no)	1995-01-09	2001-12-19	Fremgangsmåte for fremstilling av substituerte formamider

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
NO973167A NO973167L (no)	1995-01-09	1997-07-08	Bestemte 1,4,5-trisubstituerte imidazol-forbindelser anvendelige som cytokin
NO20016225A NO20016225D0 (no)	1995-01-09	2001-12-19	Fremgangsmåte for fremstilling av 1,4,5-trisubstituerte imidazolforbindelser

Country Status (33)

Country	Link
US (5)	US5593992A (no)
EP (2)	EP0809499B1 (no)
JP (2)	JP3330952B2 (no)
CN (1)	CN1138546C (no)
AP (1)	AP1270A (no)
AR (1)	AR002267A1 (no)
AT (1)	ATE254613T1 (no)
AU (1)	AU705207C (no)
BG (1)	BG63769B1 (no)
BR (1)	BR9606904A (no)
CA (1)	CA2209938A1 (no)
CZ (1)	CZ215897A3 (no)
DE (1)	DE69630777T2 (no)
DK (1)	DK0809499T3 (no)
DZ (1)	DZ1961A1 (no)
ES (1)	ES2210348T3 (no)
FI (1)	FI972901A7 (no)
HU (1)	HUP9702409A3 (no)
ID (3)	ID23597A (no)
IL (7)	IL116455A (no)
IN (3)	IN184957B (no)
MA (1)	MA23770A1 (no)
MX (1)	MX9705142A (no)
NO (3)	NO973167L (no)
NZ (1)	NZ301204A (no)
OA (1)	OA10738A (no)
PL (1)	PL322249A1 (no)
PT (1)	PT809499E (no)
RU (2)	RU2196139C2 (no)
SI (1)	SI0809499T1 (no)
SK (1)	SK90297A3 (no)
TW (1)	TW523511B (no)
WO (1)	WO1996021452A1 (no)

Families Citing this family (121)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5916891A (en) *	1992-01-13	1999-06-29	Smithkline Beecham Corporation	Pyrimidinyl imidazoles
PT724588E (pt) *	1993-09-17	2000-05-31	Smithkline Beecham Corp	Proteina de ligacao a farmacos
US6203803B1 (en)	1994-12-14	2001-03-20	Societe L'oreal S.A.	Use of a substance P antagonist in a cosmetic composition, and the composition thus obtained
CA2210322A1 (en) *	1995-01-12	1996-07-18	Smithkline Beecham Corporation	Novel compounds
EP0737471A3 (fr) *	1995-04-10	2000-12-06	L'oreal	Utilisation d'un sel d'une métal alcalino-terreux comme inhibiteur de TNF-alpha dans une composition unique et composition obtenue
IL118544A (en) *	1995-06-07	2001-08-08	Smithkline Beecham Corp	History of imidazole, the process for their preparation and the pharmaceutical preparations containing them
US6369068B1 (en)	1995-06-07	2002-04-09	Smithkline Beecham Corporation	Amino substituted pyrimidine containing compounds
US5739143A (en) *	1995-06-07	1998-04-14	Smithkline Beecham Corporation	Imidazole compounds and compositions
FR2740341B1 (fr) *	1995-10-26	1997-12-19	Oreal	Utilisation de sel de lanthanide, d'etain, de zinc, de manganese, d'yttrium, de cobalt, de baryum, de strontium dans une composition pour la peau
ZA9610687B (en) *	1995-12-22	1997-09-29	Smithkline Beecham Corp	Novel synthesis.
KR19990077164A (ko) *	1996-01-11	1999-10-25	스티븐 베네티아너	신규 치환된 이미다졸 화합물
ZA97175B (en)	1996-01-11	1997-11-04	Smithkline Beecham Corp	Novel substituted imidazole compounds.
US6046208A (en) *	1996-01-11	2000-04-04	Smithkline Beecham Corporation	Substituted imidazole compounds
AP9700912A0 (en) *	1996-01-11	1997-01-31	Smithkline Beecham Corp	Novel cycloalkyl substituted imidazoles
JP2000507224A (ja) *	1996-03-08	2000-06-13	スミスクライン・ビーチャム・コーポレイション	Ｃｓａｉｄ化合物の血管形成の抑制物質としての使用
EP0889888A4 (en) *	1996-03-25	2003-01-08	Smithkline Beecham Corp	NEW TREATMENT OF LESIONS IN THE CENTRAL NERVOUS SYSTEM
WO1998007425A1 (en) *	1996-08-21	1998-02-26	Smithkline Beecham Corporation	Imidazole compounds, compositions and use
KR20000057137A (ko)	1996-11-19	2000-09-15	스티븐 엠. 오드레	아릴 및 헤테로아릴로 치환된 융합 피롤 항염증제
US6096753A (en)	1996-12-05	2000-08-01	Amgen Inc.	Substituted pyrimidinone and pyridone compounds and methods of use
US6410729B1 (en)	1996-12-05	2002-06-25	Amgen Inc.	Substituted pyrimidine compounds and methods of use
US5929076A (en) *	1997-01-10	1999-07-27	Smithkline Beecham Corporation	Cycloalkyl substituted imidazoles
AP999A (en) *	1997-01-10	2001-08-11	Smithkline Beecham Corp	Novel substituted imidazole compounds.
US6432947B1 (en) *	1997-02-19	2002-08-13	Berlex Laboratories, Inc.	N-heterocyclic derivatives as NOS inhibitors
PT1028954E (pt)	1997-04-24	2003-11-28	Ortho Mcneil Pharm Inc	Imidazoles substituidos uteis no tratamento de doencas inflamatorias
US6514977B1 (en)	1997-05-22	2003-02-04	G.D. Searle & Company	Substituted pyrazoles as p38 kinase inhibitors
US6087496A (en)	1998-05-22	2000-07-11	G. D. Searle & Co.	Substituted pyrazoles suitable as p38 kinase inhibitors
WO1998052940A1 (en) *	1997-05-22	1998-11-26	G.D. Searle And Co.	SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS
CA2288787A1 (en)	1997-05-22	1998-11-26	G.D. Searle And Co.	Pyrazole derivatives as p38 kinase inhibitors
US5932576A (en) *	1997-05-22	1999-08-03	G. D. Searle & Company	3(5)-heteroaryl substituted pyrazoles as p38 kinase inhibitors
US6979686B1 (en)	2001-12-07	2005-12-27	Pharmacia Corporation	Substituted pyrazoles as p38 kinase inhibitors
PT988301E (pt)	1997-06-12	2006-10-31	Aventis Pharma Ltd	Acetais ciclicos de imidazolilo
CA2294057A1 (en)	1997-06-13	1998-12-17	Smithkline Beecham Corporation	Novel pyrazole and pyrazoline substituted compounds
WO1998057966A1 (en)	1997-06-19	1998-12-23	Smithkline Beecham Corporation	Novel aryloxy substituted pyrimidine imidazole compounds
JP2002515915A (ja) *	1997-06-30	2002-05-28	オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド	炎症性疾患の治療で有用な２−置換イミダゾール類
TW517055B (en) *	1997-07-02	2003-01-11	Smithkline Beecham Corp	Novel substituted imidazole compounds
US6562832B1 (en)	1997-07-02	2003-05-13	Smithkline Beecham Corporation	Substituted imidazole compounds
AR016294A1 (es) *	1997-07-02	2001-07-04	Smithkline Beecham Corp	Compuesto de imidazol sustituido, composicion farmaceutica que la contiene, su uso en la fabricacion de un medicamento y procedimiento para supreparacion
US7301021B2 (en) *	1997-07-02	2007-11-27	Smithkline Beecham Corporation	Substituted imidazole compounds
US6251914B1 (en)	1997-07-02	2001-06-26	Smithkline Beecham Corporation	Cycloalkyl substituted imidazoles
US6489325B1 (en)	1998-07-01	2002-12-03	Smithkline Beecham Corporation	Substituted imidazole compounds
EP1041989A4 (en) *	1997-10-08	2002-11-20	Smithkline Beecham Corp	NEW SUBSTITUTED CYCLOALCENYL COMPOUNDS
AU9449398A (en) *	1997-10-10	1999-05-03	Imperial College Innovations Ltd.	Use of csaidtm compounds for the management of uterine contractions
US6022884A (en)	1997-11-07	2000-02-08	Amgen Inc.	Substituted pyridine compounds and methods of use
US7041694B1 (en)	1997-12-17	2006-05-09	Cornell Research Foundation, Inc.	Cyclooxygenase-2 inhibition
EP1037639A4 (en) *	1997-12-19	2002-04-17	Smithkline Beecham Corp	HETEROARYL-SUBSTITUTED IMIDAZOLE COMPOUNDS, THEIR PHARMACEUTICAL COMPOSITIONS AND USES
CN1302296A (zh)	1998-05-22	2001-07-04	史密丝克莱恩比彻姆公司	新的2－烷基取代咪唑化合物
EP1082320A4 (en) *	1998-05-26	2001-11-21	Smithkline Beecham Corp	NEW SUBSTITUTED IMIDAZOLE COMPOUNDS
US6858617B2 (en)	1998-05-26	2005-02-22	Smithkline Beecham Corporation	Substituted imidazole compounds
WO2000001688A1 (en) *	1998-07-02	2000-01-13	Sankyo Company, Limited	Five-membered heteroaryl compounds
US6207687B1 (en) *	1998-07-31	2001-03-27	Merck & Co., Inc.	Substituted imidazoles having cytokine inhibitory activity
ATE266399T1 (de) *	1998-08-20	2004-05-15	Smithkline Beecham Corp	Neue substituierte triazolverbindungen
JP2002528506A (ja)	1998-11-04	2002-09-03	スミスクライン・ビーチャム・コーポレイション	ピリジン−４−イルまたはピリミジン−４−イル置換ピラジン
US6239279B1 (en)	1998-12-16	2001-05-29	Smithkline Beecham Corporation	Synthesis for 4-aryl-5-pyrimidine imidazole substituted derivatives
JP2002534385A (ja)	1999-01-08	2002-10-15	スミスクライン・ビーチャム・コーポレイション	新規化合物
US6930101B1 (en)	1999-05-17	2005-08-16	The Regents Of The University Of California	Thiazolopyrimidines useful as TNFα inhibitors
EP1185528A4 (en) *	1999-06-17	2003-03-26	Shionogi Biores Corp	INHIBITORS OF IL-12 PRODUCTION
IL137365A0 (en) *	1999-07-21	2001-07-24	Sankyo Co	Heteroaryl-substituted pyrrole derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
US7122666B2 (en)	1999-07-21	2006-10-17	Sankyo Company, Limited	Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses
AU1782301A (en)	1999-11-23	2001-06-04	Smithkline Beecham Corporation	3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p39 kinase inhibitors
ATE281439T1 (de)	1999-11-23	2004-11-15	Smithkline Beecham Corp	3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p38-kinase-inhibitoren
AU1783201A (en)	1999-11-23	2001-06-04	Smithkline Beecham Corporation	3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors
US6759410B1 (en)	1999-11-23	2004-07-06	Smithline Beecham Corporation	3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
US20020002169A1 (en) *	1999-12-08	2002-01-03	Griffin John H.	Protein kinase inhibitors
EP1175214B1 (en) *	1999-12-08	2004-11-24	Pharmacia Corporation	Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect
US7235551B2 (en) *	2000-03-02	2007-06-26	Smithkline Beecham Corporation	1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
US6525051B2 (en)	2000-03-27	2003-02-25	Schering Aktiengesellschaft	N-heterocyclic derivatives as NOS inhibitors
JP2004503601A (ja) *	2000-07-13	2004-02-05	ファルマシア・コーポレーション	眼のｃｏｘ−２媒介疾患の処置及び予防におけるｃｏｘ−２阻害剤の使用法
PE20020146A1 (es) *	2000-07-13	2002-03-31	Upjohn Co	Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
NZ524252A (en) *	2000-07-20	2004-03-26	Lauras As	Cox-2 inhibitors for treating HIV and AIDS
CN1847229B (zh)	2000-10-23	2011-05-04	史密丝克莱恩比彻姆公司	2，4，8-三取代-8H-吡啶并[2，3-d]嘧啶-7-酮化合物
US7115565B2 (en) *	2001-01-18	2006-10-03	Pharmacia & Upjohn Company	Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
DE60223339T2 (de)	2001-01-22	2008-08-28	Sankyo Co., Ltd.	Durch bicyclische aminogruppen substituierte verbindungen
WO2002076974A2 (en)	2001-03-26	2002-10-03	Ortho-Mcneil Pharmaceutical, Inc.	Process for the preparation of tetrasubstituted imidazole derivatives and novel crystalline structures thereof
PE20021017A1 (es)	2001-04-03	2002-11-24	Pharmacia Corp	Composicion parenteral reconstituible
WO2002094267A1 (en) *	2001-05-24	2002-11-28	Sankyo Company, Limited	Pharmaceutical composition for prevention or treatment of arthritis
UA80682C2 (en) *	2001-08-06	2007-10-25	Pharmacia Corp	Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition
CN100402521C (zh) *	2001-10-22	2008-07-16	田边制药株式会社	4-咪唑啉-2-酮化合物
AR039241A1 (es) *	2002-04-04	2005-02-16	Biogen Inc	Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
US6982259B2 (en) *	2002-04-30	2006-01-03	Schering Aktiengesellschaft	N-heterocyclic derivatives as NOS inhibitors
ES2278170T3 (es)	2002-07-09	2007-08-01	BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG	Composiciones farmaceuticas de anticolinergicos e inhibidores de la quinasa p38 en el tratamiento de enfermedades respiratorias.
US7268139B2 (en)	2002-08-29	2007-09-11	Scios, Inc.	Methods of promoting osteogenesis
UA80295C2 (en) *	2002-09-06	2007-09-10	Biogen Inc	Pyrazolopyridines and using the same
UA80296C2 (en) *	2002-09-06	2007-09-10	Biogen Inc	Imidazolopyridines and methods of making and using the same
EP1560488B1 (en)	2002-11-05	2010-09-01	Glaxo Group Limited	Antibacterial agents
PT1578731E (pt) *	2002-12-16	2010-01-12	Astrazeneca Uk Ltd	Processo para a preparação de compostos pirimidina
CL2004000234A1 (es) *	2003-02-12	2005-04-15	Biogen Idec Inc	Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
CL2004000366A1 (es) *	2003-02-26	2005-01-07	Pharmacia Corp Sa Organizada B	USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE PIRAZOL INHIBIDOR DE QUINASA p38, Y UN INHIBIDOR DE ACE PARA TRATAR DISFUNCION RENAL, ENFERMEDAD CARDIOVASCULAR Y VASCULAR, RETINOPATIA, NEUROPATIA, EDEMA, DISFUNCION ENDOTELIAL O INSULINOPATIA.
WO2005030091A2 (en)	2003-09-25	2005-04-07	Scios Inc.	Stents and intra-luminal prostheses containing map kinase inhibitors
EP1692111A2 (en) *	2003-12-12	2006-08-23	Wyeth, A Corporation of the State of Delaware	Quinolines useful in treating cardiovascular disease
CA2550064A1 (en) *	2003-12-18	2005-07-07	Pfizer Products Inc.	Methods of treating acute inflammation in animals with p38 map kinase inhibitors
EP1758892B1 (en) *	2004-06-10	2012-10-17	Irm Llc	Compounds and compositions as protein kinase inhibitors
US20060035893A1 (en)	2004-08-07	2006-02-16	Boehringer Ingelheim International Gmbh	Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
CN101010421B (zh) *	2004-08-31	2011-08-03	三洋化成工业株式会社	表面活性剂
PE20060777A1 (es)	2004-12-24	2006-10-06	Boehringer Ingelheim Int	Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
EP1676574A3 (en)	2004-12-30	2006-07-26	Johnson & Johnson Vision Care, Inc.	Methods for promoting survival of transplanted tissues and cells
UY29440A1 (es)	2005-03-25	2006-10-02	Glaxo Group Ltd	Nuevos compuestos
CN101495475A (zh) *	2005-03-25	2009-07-29	葛兰素集团有限公司	制备吡啶并[2,3-d]嘧啶-7-酮和3,4-二氢嘧啶并[4,5-d]嘧啶-2(1H)-酮衍生物的方法
TW200720272A (en) *	2005-04-22	2007-06-01	Kalypsys Inc	Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders
US20060281788A1 (en)	2005-06-10	2006-12-14	Baumann Christian A	Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
WO2007124319A1 (en) *	2006-04-20	2007-11-01	Janssen Pharmaceutica N.V.	Inhibitors of c-fms kinase
US8697716B2 (en)	2006-04-20	2014-04-15	Janssen Pharmaceutica Nv	Method of inhibiting C-KIT kinase
AU2007240437B2 (en)	2006-04-20	2012-12-06	Janssen Pharmaceutica N.V.	Heterocyclic compounds as inhibitors of c-fms kinase
EP1992344A1 (en)	2007-05-18	2008-11-19	Institut Curie	P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
EP2173876A4 (en) *	2007-06-05	2012-05-30	Western States Biopharmaceuticals Inc	T CELL CYTOKIN INDUCING SURFACE MOLECULES AND USE METHOD
JO3240B1 (ar)	2007-10-17	2018-03-08	Janssen Pharmaceutica Nv	c-fms مثبطات كيناز
WO2010091324A1 (en) *	2009-02-06	2010-08-12	Western States Biopharmaceuticals, Inc.	Dual inhibition of immunophilin/cyclophilin and emmprin immunoglobulin receptor superfamily members
RU2418582C1 (ru) *	2010-04-08	2011-05-20	Аверин Константин Михайлович	1,3-диалкилбензимидазолия галогениды - средства для лечения рассеянного склероза
JOP20180012A1 (ar)	2012-08-07	2019-01-30	Janssen Pharmaceutica Nv	عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد
EP2882757B1 (en)	2012-08-07	2016-10-05	Janssen Pharmaceutica, N.V.	Process for the preparation of heterocyclic ester derivatives
CA2882123C (en) *	2012-08-16	2021-07-20	Janssen Pharmaceutica Nv	Substituted pyrazoles as n-type calcium channel blockers
US9453002B2 (en)	2013-08-16	2016-09-27	Janssen Pharmaceutica Nv	Substituted imidazoles as N-type calcium channel blockers
CN104496906B (zh) *	2014-11-05	2016-03-23	上海浩登材料科技有限公司	一种咪唑的制备方法
CN104402823B (zh) *	2014-11-05	2016-03-23	上海浩登材料科技有限公司	一种1，2-二甲基咪唑的制备方法
WO2016149756A1 (en)	2015-03-23	2016-09-29	The University Of Melbourne	Treatment of respiratory diseases
CN110753688A (zh) *	2017-05-03	2020-02-04	墨尔本大学	用于治疗呼吸系统疾病的化合物
KR20200067170A (ko)	2017-10-05	2020-06-11	풀크럼 쎄러퓨틱스, 인코포레이티드	FSHD의 치료를 위하여 DUX4 및 하류 유전자 발현을 저감시키는 p38 키나제 저해제
US10342786B2 (en)	2017-10-05	2019-07-09	Fulcrum Therapeutics, Inc.	P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
WO2020093098A1 (en)	2018-11-07	2020-05-14	The University Of Melbourne	Novel compounds for the treatment of respiratory diseases
EP3725768A1 (en) *	2019-04-17	2020-10-21	Newron Pharmaceuticals S.p.A.	Process for the production of substituted 2-[2-(phenyl) ethylamino]alkaneamide derivatives
FR3097222B1 (fr) *	2019-06-11	2021-05-28	Michelin & Cie	Nouveaux composes 1,3-dipolaires comprenant un heterocycle aromatique et un cycle imidazole
CN118812481A (zh)	2019-08-23	2024-10-22	持田制药株式会社	杂环亚基乙酰胺衍生物的制造方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3725399A (en) *	1969-03-11	1973-04-03	Glaxo Lab Ltd	METHOD OF PRODUCING 7{62 -ACYLAMIDO-3-METHYLCEPH-3-Em-4-CARBOXYLIC ACID ESTERS
US3707475A (en) *	1970-11-16	1972-12-26	Pfizer	Antiinflammatory imidazoles
US3940486A (en) *	1971-05-10	1976-02-24	Ciba-Geigy Corporation	Imidazole derivatives in the treatment of pain
US3929807A (en) *	1971-05-10	1975-12-30	Ciba Geigy Corp	2-Substituted-4(5)-(aryl)-5(4)-(2,3 or -4-pyridyl)-imidazoles
US4058614A (en) *	1973-12-04	1977-11-15	Merck & Co., Inc.	Substituted imidazole compounds and therapeutic compositions therewith
EP0004648B1 (de) *	1978-04-11	1982-08-25	Ciba-Geigy Ag	Neue Mercaptoimidazolderivate, Verfahren zu deren Herstellung, Mercaptoimidazolderivate zur Behandlung entzündlicher Erkrankungen und diese enthaltende pharmazeutische Präparate
US4199592A (en) *	1978-08-29	1980-04-22	E. I. Du Pont De Nemours And Company	Antiinflammatory 4,5-diaryl-2-nitroimidazoles
DD201677A5 (de) *	1980-07-25	1983-08-03	Ciba Geigy	Verfahren zur herstellung von trisubstituierten imidazolderivaten
US4503065A (en) *	1982-08-03	1985-03-05	E. I. Du Pont De Nemours And Company	Antiinflammatory 4,5-diaryl 1-2-halo imidazoles
US4565875A (en) *	1984-06-27	1986-01-21	Fmc Corporation	Imidazole plant growth regulators
US4686231A (en) *	1985-12-12	1987-08-11	Smithkline Beckman Corporation	Inhibition of 5-lipoxygenase products
IE59893B1 (en) *	1986-04-16	1994-04-20	Roussel Uclaf	Process for the manufacture of n-(sulfonylmethyl) formamides
IL83467A0 (en) *	1986-08-15	1988-01-31	Fujisawa Pharmaceutical Co	Imidazole derivatives,processes for their preparation and pharmaceutical compositions containing the same
US5166400A (en) *	1989-01-19	1992-11-24	Pfizer Inc.	Intermediates for isopropyl 3S-amino-2R-hydroxy-alkanoates
AU9169991A (en) *	1990-12-13	1992-07-08	Smithkline Beecham Corporation	Novel csaids
CA2098177A1 (en) *	1990-12-13	1992-06-13	Jerry L. Adams	Csaids
MX9300141A (es) *	1992-01-13	1994-07-29	Smithkline Beecham Corp	Compuestos de imidazol novedosos, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.
DE69322254T2 (de) *	1992-01-13	1999-04-29	Smithkline Beecham Corp., Philadelphia, Pa. 19101	Pyridyl-substituierte imidazole
IL110296A (en) *	1993-07-16	1999-12-31	Smithkline Beecham Corp	Imidazole compounds process for their preparation and pharmaceutical compositions containing them
AU7629594A (en) *	1993-07-21	1995-02-20	Smithkline Beecham Corporation	Imidazoles for treating cytokine mediated disease
IL114483A0 (en) *	1994-07-12	1995-11-27	Yissum Res Dev Co	Glycinamide derivatives pharmaceutical compositions containing the same and methods utilizing the same
CA2210322A1 (en) *	1995-01-12	1996-07-18	Smithkline Beecham Corporation	Novel compounds

1995
- 1995-06-07 US US08/472,366 patent/US5593992A/en not_active Expired - Lifetime
- 1995-12-19 IL IL11645595A patent/IL116455A/en not_active IP Right Cessation
- 1995-12-19 IL IL13432295A patent/IL134322A/en not_active IP Right Cessation
- 1995-12-19 IL IL13432395A patent/IL134323A/en not_active IP Right Cessation
- 1995-12-19 IL IL13432495A patent/IL134324A/xx unknown
1996
- 1996-01-03 IN IN11DE1996 patent/IN184957B/en unknown
- 1996-01-05 AR ARP960100903A patent/AR002267A1/es unknown
- 1996-01-05 MA MA24125A patent/MA23770A1/fr unknown
- 1996-01-06 DZ DZ960002A patent/DZ1961A1/fr active
- 1996-01-09 ID IDP990849D patent/ID23597A/id unknown
- 1996-01-09 ID IDP990848D patent/ID23599A/id unknown
- 1996-01-09 ID IDP990850D patent/ID23273A/id unknown
- 1996-01-11 DE DE69630777T patent/DE69630777T2/de not_active Expired - Fee Related
- 1996-01-11 DK DK96902151T patent/DK0809499T3/da active
- 1996-01-11 FI FI972901A patent/FI972901A7/fi not_active IP Right Cessation
- 1996-01-11 RU RU97113753/04A patent/RU2196139C2/ru not_active IP Right Cessation
- 1996-01-11 AP APAP/P/1997/001021A patent/AP1270A/en active
- 1996-01-11 EP EP96902151A patent/EP0809499B1/en not_active Expired - Lifetime
- 1996-01-11 JP JP52186296A patent/JP3330952B2/ja not_active Expired - Fee Related
- 1996-01-11 AT AT96902151T patent/ATE254613T1/de not_active IP Right Cessation
- 1996-01-11 BR BR9606904A patent/BR9606904A/pt active Search and Examination
- 1996-01-11 SI SI9630660T patent/SI0809499T1/xx unknown
- 1996-01-11 ES ES96902151T patent/ES2210348T3/es not_active Expired - Lifetime
- 1996-01-11 HU HU9702409A patent/HUP9702409A3/hu unknown
- 1996-01-11 EP EP02078189A patent/EP1264827A1/en not_active Withdrawn
- 1996-01-11 NZ NZ301204A patent/NZ301204A/xx unknown
- 1996-01-11 CN CNB961922982A patent/CN1138546C/zh not_active Expired - Fee Related
- 1996-01-11 AU AU46572/96A patent/AU705207C/en not_active Ceased
- 1996-01-11 SK SK902-97A patent/SK90297A3/sk unknown
- 1996-01-11 PL PL96322249A patent/PL322249A1/xx unknown
- 1996-01-11 CZ CZ972158A patent/CZ215897A3/cs unknown
- 1996-01-11 WO PCT/US1996/000546 patent/WO1996021452A1/en not_active Ceased
- 1996-01-11 CA CA002209938A patent/CA2209938A1/en not_active Abandoned
- 1996-01-11 MX MX9705142A patent/MX9705142A/es unknown
- 1996-01-11 PT PT96902151T patent/PT809499E/pt unknown
- 1996-03-18 TW TW085103208A patent/TW523511B/zh not_active IP Right Cessation
- 1996-08-21 US US08/702,250 patent/US5663334A/en not_active Expired - Lifetime
1997
- 1997-03-17 US US08/819,619 patent/US6103936A/en not_active Expired - Fee Related
- 1997-07-02 BG BG101727A patent/BG63769B1/bg unknown
- 1997-07-08 NO NO973167A patent/NO973167L/no unknown
- 1997-07-09 OA OA70045A patent/OA10738A/en unknown
2000
- 2000-01-27 IN IN61DE2000 patent/IN188339B/en unknown
- 2000-01-27 IN IN60DE2000 patent/IN188338B/en unknown
- 2000-02-01 IL IL13432400A patent/IL134324A0/xx unknown
- 2000-02-01 IL IL13432300A patent/IL134323A0/xx unknown
- 2000-02-01 IL IL13432200A patent/IL134322A0/xx unknown
- 2000-02-11 US US09/502,763 patent/US6222036B1/en not_active Expired - Fee Related
2001
- 2001-02-27 US US09/795,009 patent/US20020188122A1/en not_active Abandoned
- 2001-07-16 JP JP2001215404A patent/JP2002105047A/ja active Pending
- 2001-12-19 NO NO20016225A patent/NO20016225D0/no not_active Application Discontinuation
- 2001-12-19 NO NO20016226A patent/NO20016226D0/no not_active Application Discontinuation
2002
- 2002-08-15 RU RU2002122174/14A patent/RU2002122174A/ru not_active Application Discontinuation

Also Published As

Publication number	Publication date
AP1270A (en)	2004-04-16
US5663334A (en)	1997-09-02
EP0809499A1 (en)	1997-12-03
WO1996021452A1 (en)	1996-07-18
IN188339B (no)	2002-09-07
IL116455A (en)	2001-07-24
BG101727A (bg)	1998-03-31
EP0809499A4 (en)	1998-10-14
IL134324A0 (en)	2001-04-30
DZ1961A1 (fr)	2002-02-17
IL134323A (en)	2001-11-25
BG63769B1 (bg)	2002-12-29
RU2002122174A (ru)	2004-02-27
FI972901A0 (fi)	1997-07-08
MX9705142A (es)	1997-10-31
US6222036B1 (en)	2001-04-24
IL116455A0 (en)	1996-03-31
AP9701021A0 (en)	1997-07-31
US5593992A (en)	1997-01-14
AU4657296A (en)	1996-07-31
ID23273A (id)	1996-10-10
DE69630777D1 (de)	2003-12-24
RU2196139C2 (ru)	2003-01-10
ID23599A (id)	1996-10-10
HUP9702409A2 (hu)	1999-05-28
EP1264827A1 (en)	2002-12-11
MA23770A1 (fr)	1996-10-01
NO20016225L (no)	1997-09-08
AR002267A1 (es)	1998-03-11
EP0809499B1 (en)	2003-11-19
SK90297A3 (en)	1998-01-14
ES2210348T3 (es)	2004-07-01
AU705207B2 (en)	1999-05-20
PL322249A1 (en)	1998-01-19
OA10738A (en)	2002-12-11
IL134322A (en)	2001-09-13
DK0809499T3 (da)	2004-03-29
IL134324A (en)	2001-08-26
IN184957B (no)	2000-10-07
DE69630777T2 (de)	2004-07-29
ATE254613T1 (de)	2003-12-15
CN1177299A (zh)	1998-03-25
CN1138546C (zh)	2004-02-18
IL134323A0 (en)	2001-04-30
TW523511B (en)	2003-03-11
CA2209938A1 (en)	1996-07-18
AU705207C (en)	2002-09-19
JP2002105047A (ja)	2002-04-10
JPH10512555A (ja)	1998-12-02
HK1003623A1 (en)	1999-02-12
HUP9702409A3 (en)	1999-06-28
IN188338B (no)	2002-09-07
JP3330952B2 (ja)	2002-10-07
NO20016226L (no)	1997-09-08
FI972901L (fi)	1997-09-08
IL134322A0 (en)	2001-04-30
US20020188122A1 (en)	2002-12-12
NO20016225D0 (no)	2001-12-19
US6103936A (en)	2000-08-15
BR9606904A (pt)	1997-10-21
NZ301204A (en)	1999-05-28
PT809499E (pt)	2004-04-30
NO973167L (no)	1997-09-08
CZ215897A3 (cs)	1998-04-15
ID23597A (id)	1996-10-10
SI0809499T1 (en)	2004-04-30
FI972901A7 (fi)	1997-09-08
NO973167D0 (no)	1997-07-08

Publication	Publication Date	Title
NO20016226D0 (no)	2001-12-19	Fremgangsmåte for fremstilling av substituerte formamider
AU7062496A (en)	1997-05-15	Process for the production of Bis(silyalkyl)-disulfanes
FI971609L (fi)	1997-06-02	Menetelmä 4a,5,9,10,11,12-heksahydro-6H-bentsofuro-(3a,3,2-ef)(2)-bentsatsepiinijohdannaisten valmistamiseksi
NO981800D0 (no)	1998-04-22	FremgangsmÕte for fremstilling av 1,1,1,3,3-pentafluorpentan
FI973281L (fi)	1997-08-08	Menetelmä tiettyjen atsasykloheksapeptidien valmistamiseksi
ATE227723T1 (de)	2002-11-15	Eintopfverfahren zur herstellung von 2- oxazolidinonderivate
NO974169D0 (no)	1997-09-09	Fremgangsmåte for tetra-azacykloalkan-fremstilling
AU9149191A (en)	1992-07-08	Process for producing acrolein
NO982237D0 (no)	1998-05-15	Ny fremgangsmÕte for fremstilling av fenylimidazolidinderivater
ES2086065T3 (es)	1996-06-16	Preparacion de tetrahidropiridinas sustituidas.
AU649632B2 (en)	1994-06-02	Process for the synthesis of cyclic polynitrogenated compounds
NO924690D0 (no)	1992-12-04	Fremgangsmaate for fremstilling av mono-n-substituerte tetraazakrocykluser
NO930574D0 (no)	1993-02-18	Fremgangsmaate for fremstilling av desfluran
ES2087129T3 (es)	1996-07-16	Sintesis enantioselectiva de antifoliatos.
NO974155D0 (no)	1997-09-09	Ny fremgangsmåte for fremstilling av 2,3-dihydrobenzofuranolderivater
NO179101C (no)	1996-08-07	Fremgangsmåte for fremstilling av dibeskyttet 2,3-hydroksymetyl-cyklobutanol
DE69115090D1 (de)	1996-01-18	Verfahren zur Herstellung von Fluormethyl-substituierten Pyridin-carbodithioaten.
PH23992A (en)	1990-02-09	Optically active 2,3-dihydrobenzoxazine derivatives and process for preparing the same
FI900296A7 (fi)	1990-07-22	Menetelmä esi-insuliinin valmistamiseksi
ES2089176T3 (es)	1996-10-01	Procedimiento para la preparacion de carboditioatos de piperidina fluorometil-sustituidos.
FI952462L (fi)	1995-05-19	Menetelmä 1,3-oksatsolidin-5-karboksyylihapon valmistamiseksi
FI930237A7 (fi)	1993-07-24	Menetelmä 4,6-dialkoksipyrimidiinien valmistamiseksi
DK0431305T3 (da)	1995-04-03	Fremgangsmåde til fremstilling af molluskicide 2,4,5-tribrompyrrol-3-carbonitriler
NO964519D0 (no)	1996-10-24	Fremgangsmåte for fremstilling av chitosanalkylderivater
NO963174D0 (no)	1996-07-30	Fremgangsmåte for fremstilling av isovanillin

Legal Events

Date	Code	Title	Description
2005-09-26	FC2A	Withdrawal, rejection or dismissal of laid open patent application